Unveiling Illumina (ILMN) Q1 Outlook: Wall Street Estimates for Key Metrics

05.05.25 15:15 Uhr

Werte in diesem Artikel
Aktien

65,58 EUR -3,20 EUR -4,65%

Indizes

5.606,9 PKT -43,5 PKT -0,77%

Wall Street analysts forecast that Illumina (ILMN) will report quarterly earnings of $0.96 per share in its upcoming release, pointing to a year-over-year increase of 966.7%. It is anticipated that revenues will amount to $1.04 billion, exhibiting a decline of 3.5% compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 0.6% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.Given this perspective, it's time to examine the average forecasts of specific Illumina metrics that are routinely monitored and predicted by Wall Street analysts.Analysts expect 'Revenue- Product revenue- Consumable' to come in at $763.09 million. The estimate indicates a year-over-year change of +0.1%.The consensus estimate for 'Revenue- Service and other revenue' stands at $170.12 million. The estimate suggests a change of -14.9% year over year.Analysts predict that the 'Revenue- Product revenue' will reach $872.04 million. The estimate indicates a year-over-year change of -0.5%.Based on the collective assessment of analysts, 'Revenues- Core Illumina- Service and other revenue' should arrive at $175.08 million. The estimate indicates a year-over-year change of +1.2%.The consensus among analysts is that 'Revenues- Core Illumina- Total product revenue' will reach $869.69 million. The estimate suggests a change of -1.5% year over year.The combined assessment of analysts suggests that 'Revenue- Product revenue- Instruments' will likely reach $108.95 million. The estimate indicates a change of -4.4% from the prior-year quarter.Analysts' assessment points toward 'Revenues- Core Illumina- Consumables' reaching $748.87 million. The estimate indicates a change of -2.6% from the prior-year quarter.According to the collective judgment of analysts, 'Revenue- Sequencing- Instruments' should come in at $108.51 million. The estimate points to a change of -1.4% from the year-ago quarter.The collective assessment of analysts points to an estimated 'Revenue- Sequencing- Consumables' of $679.85 million. The estimate suggests a change of -2.6% year over year.It is projected by analysts that the 'Revenue- Microarrays- Instruments' will reach $3.61 million. The estimate indicates a change of -9.9% from the prior-year quarter.The average prediction of analysts places 'Revenue- Microarrays- Consumables' at $74.59 million. The estimate indicates a year-over-year change of +5.1%.Analysts forecast 'Revenue- Core Illumina' to reach $1.03 billion. The estimate indicates a year-over-year change of -2.1%.View all Key Company Metrics for Illumina here>>>Shares of Illumina have demonstrated returns of +5% over the past month compared to the Zacks S&P 500 composite's +0.4% change. With a Zacks Rank #3 (Hold), ILMN is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Illumina, Inc. (ILMN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Illumina und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Illumina

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Illumina

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Illumina Inc.

Wer­bung

Analysen zu Illumina Inc.

DatumRatingAnalyst
30.07.2019Illumina HoldCanaccord Adams
30.05.2019Illumina OutperformWolfe Research
09.10.2018Illumina NeutralUBS AG
31.07.2018Illumina BuyCanaccord Adams
31.01.2018Illumina OverweightFirst Analysis Securities
DatumRatingAnalyst
30.05.2019Illumina OutperformWolfe Research
31.07.2018Illumina BuyCanaccord Adams
31.01.2018Illumina OverweightFirst Analysis Securities
25.10.2017Illumina OutperformRobert W. Baird & Co. Incorporated
23.10.2017Illumina BuyDeutsche Bank AG
DatumRatingAnalyst
30.07.2019Illumina HoldCanaccord Adams
09.10.2018Illumina NeutralUBS AG
05.01.2018Illumina NeutralBTIG Research
02.08.2017Illumina Equal-WeightFirst Analysis Securities
26.04.2017Illumina NeutralCantor Fitzgerald
DatumRatingAnalyst
02.11.2016Illumina UnderweightFirst Analysis Securities

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Illumina Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen